Rituximab in Pemphigus – An Observational Study from a Tertiary Care Center of North India

BACKGROUND: Pemphigus is a group of potentially fatal autoimmune mucocutaneous blistering diseases. Rituximab (RTX) is a chimeric anti-CD20 (anti-cluster of differentiate 20) monoclonal antibody being increasingly used and becoming the first-line therapy in the management of pemphigus. AIMS AND OBJE...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassan, Iffat, Rehman, Fozia, Sultan, Sheikh Javeed, Aslam, Aaqib, Tasaduq, Irfan, Reyaz, Saika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9595168/
https://www.ncbi.nlm.nih.gov/pubmed/36304644
http://dx.doi.org/10.4103/idoj.idoj_170_22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9595168/
https://www.ncbi.nlm.nih.gov/pubmed/36304644
http://dx.doi.org/10.4103/idoj.idoj_170_22

Ejemplares similares